All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-03-07T09:35:54.000Z

FDA approves sBLA for new four-week dosing schedule of nivolumab

Mar 7, 2018
Share:

Bookmark this article

It was announced in a press release that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a four-week dosing schedule of nivolumab on 6 March 2018. This follows a license application that was submitted in July 2017

Previously, the recommended dosing of nivolumab was 3mg/kg administered as an intravenous infusion over 60 minutes every two weeks until disease progression or unacceptable toxicity. The approval will update the dosing schedule so that physicians have the option of giving patients 480mg infused every four weeks. This new dosing schedule has been approved for relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or three or more lines of therapy that includes HSCT.

Johanna Mercier, head of U.S. Commercial at Bristol-Myers Squibb stated in the press release that, “with this approval, we now offer the most robust range of dosing options for an Immuno-Oncology medicine, providing enhanced flexibility to help address each patient’s specific needs.”

Nivolumab is a fully humanized IgG4 monoclonal antibody that targets Programmed Death-1 (PD-1) and prevents its activation by its ligands Programmed Death Ligand 1 and 2 (PD-L1/PD-L2). Opdivo® was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world in July 2014.

  1. Business Wire. Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing. 2018 Mar 06. https://www.businesswire.com/news/home/20180306005877/en. [Accessed 2018 Mar 07]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox